"10.1371_journal.pone.0035927","plos one","2012-06-06T00:00:00Z","Finn Sellebjerg; Martin Krakauer; Signe Limborg; Dan Hesse; Henrik Lund; Annika Langkilde; Helle Bach Søndergaard; Per Soelberg Sørensen","Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Danish Research Centre for Magnetic Resonance, Section 340, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark; Department of Radiology, Copenhagen University Hospital Rigshopitalet, Copenhagen, Denmark","Conceived and designed the experiments: FS MK PSS. Performed the experiments: MK HBS DH SL HL. Analyzed the data: FS MK SL AL HL HBS PSS DH. Wrote the paper: FS MK SL AL HL HBS PSS DH.","Finn Sellebjerg has served on scientific advisory boards for and received funding for travel from Biogen Idec, Merck-Serono, Novartis, Sanofi-Aventis and Teva; served as a consultant for Biogen Idec and Novo Nordisk; received speaker honoraria from Bayer-Schering, Biogen Idec, Merck-Serono, Novartis, Sanofi-Aventis and Schering-Ploug; has received research support from Biogen Idec, Merck-Serono, Novartis and Sanofi-Aventis; and serves as section editor on Multiple Sclerosis and Related Disorders. Dan Hesse has received funding for travel from Biogen Idec, Merck-Serono, and Sanofi-Aventis; and received speaker honoraria from Sanofi-Aventis and Biogen Idec. Signe Limborg reports no disclosures. Helle Bach Søndergaard reports no disclosures. Martin Krakauer reports no disclosures. Per Soelberg Sorensen has served on scientific advisory boards Biogen Idec, Merck Serono, Novartis, Genmab, TEVA, Elan, GSK, has been on steering committees or independent data monitoring boards in clinical trials sponsored by Merck Serono, Genmab, TEVA, GSK, Bayer Schering, and has received funding of travel for these activities; has served as Editor-in-Chief of the European Journal of Neurology, and is editorial board member for Therapeutic Advances in Neurological Disorders and Multiple Sclerosis; has received speaker honoraria from Biogen Idec, Merck Serono, TEVA, Bayer Schering, Sanofi-aventis, and Novartis; and has received research support from Biogen Idec, Bayer Schering, Merck Serono, TEVA, Baxter, Sanofi-Aventis, BioMS, Novartis, Bayer, RoFAR, Roche, Genzyme, from the Danish Multiple Sclerosis Society, the Danish Medical Research Council, and the European Union Sixth Framework Programme: Life sciences, Genomics and Biotechnology for health. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials.","2012","06","Finn Sellebjerg","FS",8,TRUE,3,5,8,8,TRUE,TRUE,FALSE,0,NA,FALSE
